How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,741 results for

Uveitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} One RCT of adalimumab and one RCT of dexamethasone showed significant benefits over placebo in adults with active non-infectious posterior-segment uveitis, but there is uncertainty around cost-effectiveness of both drugs. {{author}} {{($index , , , , , , , , & . Hazel Squires

2017 NIHR HTA programme

2. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis (...) for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technology Assessment 2017; 21(68) Authors' objectives To evaluate the clinical effectiveness and cost-effectiveness of subcutaneous adalimumab (Humira®; AbbVie Ltd, Maidenhead, UK) and a dexamethasone intravitreal implant (Ozurdex®; Allergan Ltd, Marlow, UK) in adults with non-infectious intermediate uveitis, posterior uveitis or panuveitis. Authors' conclusions Two RCTs of systemic adalimumab and one RCT

2018 Health Technology Assessment (HTA) Database.

3. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Adding adalimumab to methotrexate reduced the average risk over time of treatment failure in refractory uveitis associated with juvenile idiopathic arthritis by 75%. {{author}} {{($index , , , , , , , , , , , , , , , , , & . Athimalaipet V Ramanan 1, 2, * , Andrew D Dick 3, 4, 5 , Ashley P Jones 6 , Dyfrig A Hughes 7 , Andrew McKay 6 , Anna Rosala-Hallas 6 , Paula R Williamson 6

2019 NIHR HTA programme

4. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis Fluocinolone acetonide intr Fluocinolone acetonide intra avitreal vitreal implant for treating recurrent non- implant for treating recurrent non- infectious uv infectious uveitis eitis T echnology appraisal guidance Published: 31 July 2019 www.nice.org.uk/guidance/ta590 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

5. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood ( (PubMed)

Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood ( JIA-associated uveitis (JIAU) is a serious, sight-threatening disease with significant long-term complications and risk of blindness, even with improved contemporary treatments. The MIWGUC was set up in order to propose specific JIAU activity (...) . The meeting used the same Delphi and nominal group technique as previously described in the first paper from the MIWGUC group (Arthritis Care Res 64:1365-72, 2012). Patients were included with a diagnosis of JIA, aged less than 18 years, and with active uveitis or an uveitis flare which required treatment with a disease-modifying anti-rheumatic drug. The proposed outcome measures for uveitis were collected by an ophthalmologist and for arthritis by a paediatric rheumatologist. Patient reported outcome

2019 Pediatric Rheumatology

6. Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease

Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease EMA/85985/2019 EMEA/H/C/004475 Idacio (adalimumab) An overview of Idacio and why it is authorised in the EU What is Idacio and what is it used for? Idacio is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions: • plaque (...) arthritis (both rare diseases causing inflammation in the joints); • Crohn’s disease (a disease causing inflammation of the gut); • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut); • hidradenitis suppurativa (also known as acne inversa, a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin); • non-infectious uveitis (inflammation of the layer beneath the white of the eyeball). Idacio is mostly used in adults when

2019 European Medicines Agency - EPARs

9. Uveitis

Uveitis Uveitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Uveitis Last reviewed: February 2019 Last updated: March 2018 Summary Anterior uveitis involves inflammation of the iris and ciliary body. Intermediate uveitis involves the posterior ciliary body and pars plana. Posterior uveitis involves the posterior vitreous, retina, choroid, retinal vasculature, and optic nerve. Panuveitis involves inflammation (...) in the anterior, intermediate, and posterior segments of the eye. All types of uveitis are potentially blinding conditions and should be referred to and managed by an experienced ophthalmologist. Diagnosis is clinical. Acute anterior uveitis may be idiopathic, or associated with HLA-B27-related disease or viral eye disease. Posterior uveitis is associated with localised infections or systemic infection, or systemic inflammatory disease. Diagnosis of underlying disease may require investigation

2018 BMJ Best Practice

10. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. (PubMed)

Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Non-infectious uveitis describes a heterogenous group of ocular disorders characterised by intraocular inflammation in the absence of infection. Uveitis is a leading cause of visual loss, most commonly due to uveitic macular oedema (UMO). Treatment is aimed at reducing disease activity by suppression of the intraocular inflammatory response. In the case of macular (...) controlled trials that demonstrate the efficacy of anti-TNF agents in preventing recurrence of inflammation in uveitis, the reported study outcomes do not include changes in UMO. As a result, there were insufficient data to conclude whether there was a significant treatment effect specifically for UMO. Future trials should be designed to include quantitative measures of UMO as primary study outcomes, for example by reporting the presence or absence of UMO, or by measuring central macular thickness

2018 Cochrane

11. Adalimumab (Hefiya) - Juvenile Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Hefiya) - Juvenile Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 EMA/CHMP/520007/2018 Committee for Medicinal (...) and Extension Period UC Ulcerative colitis UF/DF Ultrafiltration/ Diafiltration ULOQ Upper limit of quantification US-Humira US-licensed Humira® UV Uveitis Assessment report EMA/CHMP/520007/2018 Page 7/128 WCB Working Cell Bank WFI Water for Injection Assessment report EMA/CHMP/520007/2018 Page 8/128 1 Background information on the procedure 1.1 Submission of the dossier The applicant Sandoz GmbH submitted on 23 November 2017 an application for marketing authorisation to the European Medicines Agency (EMA

2018 European Medicines Agency - EPARs

12. Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 (...) set Treatment Period 2 and Extension Period UC Ulcerative colitis UF/DF Ultrafiltration/ Diafiltration ULOQ Upper limit of quantification US-Humira US-licensed Humira® UV Uveitis Assessment report EMA/CHMP/519681/2018 Page 7/128 WCB Working Cell Bank WFI Water for Injection Assessment report EMA/CHMP/519681/2018 Page 8/128 1 Background information on the procedure 1.1 Submission of the dossier The applicant Sandoz GmbH submitted on 23 November 2017 an application for marketing authorisation

2018 European Medicines Agency - EPARs

13. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) to or have medical contraindications for such therapies. Uveitis Hyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Paediatric uveitis Hyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate

2018 European Medicines Agency - EPARs

14. Uveitis (Anterior, Acute and Recurrrent)

Uveitis (Anterior, Acute and Recurrrent) Uveitis (anterior, acute and recurrent) submit The College submit You're here: Uveitis (anterior, acute and recurrent) Uveitis (anterior, acute and recurrent) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Please login to view the images or . Aetiology Uveitis (anterior) Anterior uveitis (the most (...) common form of uveitis; annual incidence 12 per 100,000) iritis: inflammation predominantly affects iris iridocyclitis (more common): inflammation predominantly affects iris and anterior part of ciliary body (pars plicata) The Standardisation of Uveitis Nomenclature (SUN) working group has developed an international standard for classifying uveitis: Onset: sudden or insidious Duration: limited, if it is ≤3 months, or persistent, i.e. >3 months in duration Recurrent: describes repeated episodes

2019 College of Optometrists

15. Genetic aspects of idiopathic paediatric uveitis and juvenile idiopathic arthritis associated uveitis in Chinese Han. (PubMed)

Genetic aspects of idiopathic paediatric uveitis and juvenile idiopathic arthritis associated uveitis in Chinese Han. Idiopathic paediatric uveitis (IPU) and juvenile idiopathic arthritis associated uveitis (JIA-U) are the two most common entities in paediatric uveitis. This study addressed the possible association of IPU and JIA-U with genes that had been shown earlier to be associated with juvenile idiopathic arthritis.We carried out a case-control association study involving 286 IPU, 134 JIA

Full Text available with Trip Pro

2019 British Journal of Ophthalmology

16. Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis. (PubMed)

Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis. To evaluate the role of vitreomacular adhesion (VMA) in visual and anatomic outcomes in patients with non-infectious uveitis.Phase 2 clinical trial PARTICIPANTS: Data from the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Non-infectious Uveitis (STOP-Uveitis) study was analyzed.In the STOP-Uveitis study, patients with non-infectious uveitis (NIU (...) -corrected visual acuity (BCVA), central retinal thickness (CRT), and vitreous haze (VH) at M6.Out of 37 patients randomized in the STOP-Uveitis study, 48 eyes (27 patients) were eligible based on the study criteria. At baseline, 19 eyes were classified as VMA+, and 32 eyes were classified as VMA-. The distribution of two doses of TCZ (4 mg/kg and 8 mg/kg) were similar between the two groups. At M6, the mean improvement in BCVA was 2.00 ± 5.3 and 6.50 ± 7.98 letters in the VMA+ and VMA- groups

2019 Journal of ophthalmic inflammation and infection Controlled trial quality: uncertain

17. Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis

Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User (...) Password Log in × Reset password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × September 2017. Volume 13. Number 3 Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email

2017 Evidencias en Pediatría

18. Guidance for Screening for Uveitis in Juvenile Idiopathic Arthritis (JIA)

Guidance for Screening for Uveitis in Juvenile Idiopathic Arthritis (JIA) Guid ance for Screening for Uveitis in Juvenile Idiopathic Arthritis (JIA) June 2018 Aim of the screening programme To reduce the incidence of visual impairment among children and young people with juvenile idiopathic arthritis (JIA) by early detection through screening allowing for early intervention. Background The prevalence of uveitis in JIA is approximately 8-30%, but in a young oligo-articular onset group (i.e (...) . arthritis in which up to four joints are involved) it may be as high as 45-57%. The annual incidence of JIA in the UK is 1:10,000 with a prevalence of 1:1000. The type of arthritis and age at onset dictates the risk of developing uveitis. Only the highest risk groups are included in the regular screening recommendations below. However, late onset of first uveitis diagnosis can occur even in young adults and cases have been reported in systemic JIA. Therefore, it is important to make clinical referrals

2018 British Society for Rheumatology

19. Corticosteroid implants for chronic non-infectious uveitis. (PubMed)

Corticosteroid implants for chronic non-infectious uveitis. Uveitis is a term used to describe a heterogeneous group of intraocular inflammatory diseases of the anterior, intermediate, and posterior uveal tract (iris, ciliary body, choroid). Uveitis is the fifth most common cause of vision loss in high-income countries, accounting for 5% to 20% of legal blindness, with the highest incidence of disease in the working-age population.Corticosteroids are the mainstay of acute treatment for all (...) anatomical subtypes of non-infectious uveitis and can be administered orally, topically with drops or ointments, by periocular (around the eye) or intravitreal (inside the eye) injection, or by surgical implantation.To determine the efficacy and safety of steroid implants in people with chronic non-infectious posterior uveitis, intermediate uveitis, and panuveitis.We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (Issue 10, 2015), Ovid MEDLINE, Ovid MEDLINE In-Process

Full Text available with Trip Pro

2016 Cochrane

20. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. (PubMed)

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics.The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient (...) to assure optimal use of noncorticosteroid systemic immunomodulatory agents.An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID

Full Text available with Trip Pro

2018 Ophthalmology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>